This paper reviews the European Union mandatory Vigilance Reporting System and voluntary user reporting systems for medical devices. Differences between these systems and the reporting system for pharmaceuticals are highlighted. Device vigilance is run as a single harmonized system within the European Union and increasingly there are international links. Recent trends in reporting patterns within the United Kingdom are highlighted along with initiatives to improve the number and accuracy of reports. Drug/device combination products are becoming increasingly important. The handling of adverse events for these and other new technology products are described.
VincentCANedGWoloshynowychM. Adverse events in British hospitals: A preliminary retrospective review. BMJ. 2001; 332:517–519.
6.
Department of Health.An Organisation with a Memory: report of an expert group on learning from adverse events in the NHS, chaired by the Chief Medical Officer. London, United Kingdom: Department of Health, The Stationary Office: 2000.
7.
Design for Patient Safety 2003. ISBN 84182 765 7. London, United Kingdom: Department of Health; 2003.
8.
Adverse Incident Reports 2003. London, United Kingdom: Medicines and Healthcare Products Regulatory Agency; March 2004 (MHRA DB 2004).
9.
JefferysDB. An overview of recent developments in the European regulation of medicine/medical device combination products. Drug Inf J.2003; 37:239–243.
